Literature DB >> 2877169

When should levodopa be started?

N Quinn, P Critchley, D Parkes, C D Marsden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2877169     DOI： 10.1016/s0140-6736(86)90642-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Authors:  C E Clarke; J M Speller
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Lisuride for levodopa-induced complications in Parkinson's disease.

Authors:  C E Clarke; J M Speller
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.

Authors:  K H O Deane; S Spieker; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 4.  Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

Authors:  K H O Deane; S Spieker; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 5.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 6.  Amantadine for dyskinesia in Parkinson's disease.

Authors:  N J Crosby; K H O Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.